Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.
about
Beyond CA125: the coming of age of ovarian cancer biomarkersFamily information service participation increases the rates of mutation testing among members of families with BRCA1/2 mutationsPathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.The preclinical natural history of serous ovarian cancer: defining the target for early detectionPrecursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics.Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management.Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests.Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up studySurveillance of women at high risk for hereditary ovarian cancer is inefficient.Management options after prophylactic surgeries in women with BRCA mutations: a review.Primary peritoneal cancer in BRCA carriers after prophylactic bilateral salpingo-oophorectomy.Cancer surveillance based on imaging techniques in carriers of BRCA1/2 gene mutations: a systematic review.Reduced Ovarian Cancer Incidence in Women Exposed to Low Dose Ionizing Background Radiation or Radiation to the Ovaries after Treatment for Breast Cancer or Rectosigmoid CancerNew insights into the pathogenesis of serous ovarian cancer and its clinical impactTamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.Epigenetic biomarkers in the diagnosis of ovarian cancer.Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction.Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.Laparoscopic Risk-Reducing Salpingo-Oophorectomy: The Brigham and Women's Experience
P2860
Q24651567-C85777C2-972E-49BF-BE42-5E1F52E84C69Q24655010-56C7C788-8111-4E49-A82B-98A0B1C55141Q30370475-2E69A698-3C0C-423C-85B7-4D12158409D9Q33286372-17345713-BB2C-47BB-9873-C48BCDA2074AQ33487678-FD2776BF-40FF-471F-9896-EDEB3F33CBCCQ33815261-B24F4F46-9783-4B9A-9F90-6C6F0AB2F49AQ34172655-060DD50A-F955-44F9-B80B-2E78DE7DACC7Q34977063-EDD49261-2B77-4D4F-B181-2AEE8CC13A2DQ35596203-49A3E4C0-5717-4EB0-A699-5BC84061721FQ35749439-5B30805D-5213-491F-B3DE-486954CDF140Q36240959-AEF570A4-0643-40A5-8C27-EAE924F65041Q36610368-FD4AF1C4-8A1C-4AB4-BA95-D9F38CB4193FQ36614506-7A26DA0E-50C4-440D-BE3C-13788C5760AEQ36959824-67EEE7D6-6EAD-426F-B9AA-054BEF850300Q37042357-2F8BAD5E-5F17-4E56-B2BA-B3E407731C49Q37061630-AE5786D9-0B2D-4F09-AD80-83427F98DE66Q37103750-7C29AA23-765F-4FDB-8F0C-32B1AD23358EQ37119411-ADF0FEB1-55AA-42C3-80B7-E792498A1DF4Q37122297-85D93B00-D42A-4BD8-A5C5-AD61C6BC955AQ39453522-043CD62C-0F87-459B-BE47-03C7CAD49691Q41195564-70AC9075-6E33-4D85-98A8-85D465957B31Q44498721-F0637585-EAA1-46E6-95AA-BDFA93322030Q44696764-7FEE8B41-3B3B-43BE-9FF1-71A2E758FE50Q58692289-8058DDFE-C1DB-462E-89BA-1832147577DE
P2860
Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Outcome of surveillance and pr ...... high risk for ovarian cancer.
@en
Outcome of surveillance and pr ...... high risk for ovarian cancer.
@nl
type
label
Outcome of surveillance and pr ...... high risk for ovarian cancer.
@en
Outcome of surveillance and pr ...... high risk for ovarian cancer.
@nl
prefLabel
Outcome of surveillance and pr ...... high risk for ovarian cancer.
@en
Outcome of surveillance and pr ...... high risk for ovarian cancer.
@nl
P2093
P1433
P1476
Outcome of surveillance and pr ...... high risk for ovarian cancer.
@en
P2093
Cecile T M Brekelmans
Curt W Burger
Hanne J Meijers-Heijboer
Jan G M Klijn
Paul A M Meeuwissen
P304
P356
10.1016/J.YGYNO.2005.01.024
P407
P577
2005-05-01T00:00:00Z